General Category > Health/Education

Vaccines Forever: Pfizer Data Claims Third Jab ‘Strongly Boosts’ Protection Against Coronavirus Delt

(1/4) > >>

mystery-ak:
Vaccines Forever: Pfizer Data Claims Third Jab ‘Strongly Boosts’ Protection Against Coronavirus Delta Variant

Hannah Bleau 28 Jul 2021

Pfizer/BioNTech data released Wednesday suggests a third dose of the vaccine “strongly boosts” protection against the coronavirus delta variant.

The data, which the company is expected to discuss in an earnings call on Wednesday, claims a third shot of the Pfizer vaccine can “boost” protection against the virus variant.

“COVID-19 Vaccine: 3rd Dose Strongly Boosts Neutralizing Titers Against Delta Strain1,2,” page 27 of the slide presentation reads. It goes on to suggest that the antibody levels against the delta variant are greater than five-fold for those ages 18 to 55 after a third shot, and it is more than 11-fold for individuals ages 65 to 85.

more
https://www.breitbart.com/politics/2021/07/28/vaccines-forever-pfizer-data-claims-third-jab-strongly-boosts-protection-against-coronavirus-delta-variant/

Kamaji:
How long after the third shot?

skeeter:
These pharmaceutical companies are beneath contempt.

PeteS in CA:
Like two-shot vaccine protocols, "Boosters" are hardly unusual in the world of vaccines. I think the recommended period for Tetanus is 5 years. That said ...

I suspect this was part of a process begun a week or two ago. Pfizer (and others) have been testing variant-updated boosters/versions for several months. Pfizer requested an update to their EUA to include the recommendation of a third, booster, shot. The FDA replied that the existing vaccine protocol seems adequate and that there did not seem to be sufficient need to justify such a situation. My guess is that if the info in the OP article isn't from Pfizer's initial request, the info is Pfizer's response.

Contrary to the inflammatory OP article title, the whole process is actually quite ordinary. And if the FDA ultimately declines Pfizer's request, the same would be likely to happen if Moderna requests a similar update.

J&J's effectiveness in its Phase 3 test having been lower and J&J having begun testing a 2-dose regimen, hypothetically J&J could request and get an update to a 2-dose protocol. In the context of the US' vaccination process, J&J is less than 5% of US vaccinations. Such a request might be declined simply because J&J is not a significant player, as well as their original single-dose effectiveness being sufficient.

Several potential upcoming events in Covid vaccines I think more significant:

* Moderna has applied to have their EUA updated to allow youths age 12-17 to receive their vaccine;

* Pfizer and Moderna have both both begun the process that would lead to both receiving a Biologics License; in plain English, full FDA approval;

* Novavax will soon be applying for Emergency Use Authorization for their vaccine; [Snark] Anti-vaxxers will then have a third different vaccine technology to lie about. [/Snark] :silly:

thackney:

--- Quote from: PeteS in CA on July 28, 2021, 05:28:06 pm ---* Novavax will soon be applying for Emergency Use Authorization for their vaccine; [Snark] Anti-vaxxers will then have a third different vaccine technology to lie about. [/Snark] :silly:

--- End quote ---

Contains Nanoparticles to make you part of the Matrix.  I read it in the study report.

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
https://www.nejm.org/doi/full/10.1056/NEJMoa2107659
June 30, 2021

Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population...

...A two-dose regimen of the NVX-CoV2373 vaccine administered 21 days apart was found to be safe and 89.7% effective against symptomatic Covid-19 caused by both B.1.1.7 and non-B.1.1.7 variants....

...the efficacy estimate of 96.4% against the non-B.1.1.7 strains ...

Navigation

[0] Message Index

[#] Next page